Global Microbiome Therapeutics Market Trends, Forecast Report 2025-2037
Microbiome Therapeutics Market size is projected to increase from USD 531.37 million to USD 8.59 billion, demonstrating a CAGR of over 23.6% during the forecast period, from 2025 through 2037. In the year 2025, the industry size of microbiome therapeutics is assessed at USD 632.54 million.
The market growth is driven by increasing proportion of several diseases comprising inflammatory bowel disease (IBD), obesity, allergic disorders, and so on caused by dysbiosis of microbiota in the gut across the world. For instance, currently, there are nearly 11 million individuals have been suffering from inflammatory bowel disease (IBD) across the globe. Further, the growing concerns amongst individuals about the beneficial microorganisms in the human body, growing age, and unhealthy lifestyle patterns will boost the global market size.
In addition, radically rising investments in microbiome modulators, and escalating collaboration between major key players for producing novel microbiome therapeutics will fuel the microbiome therapeutics market growth. For instance, on February 1, 2023, The University of Texas MD Anderson Cancer Center announced a strategic partnership with the global biopharma institute Federation Bio to rationally produce a novel microbiome treatment for immunotherapy-resistant cancer patients. Additionally, surging awareness regarding microbiome therapeutics will spur the market expansion.

Microbiome Therapeutics Sector: Growth Drivers and Challenges
Growth Drivers
-
Worldwide Growing Prevalence of Diabetes – Diabetes is a chronic disorder that arises when the pancreas does not make enough insulin or when the body does not use the insulin adequately that is produced. The gut microbiota has been related to the development of several metabolic syndromes including diabetes through reduced glucose tolerance and insulin sensitivity. Hence, the rising prevalence of diabetes is estimated to propel the growth of the market over the forecast period. For instance, in 2021, diabetes affected around 540 million individuals throughout the world. Moreover, by 2030, this figure is expected to climb to nearly 648 million.
-
An Upsurge in Obesity - Obesity is a complicated condition defined by an excess of body fat. It's a medical condition that escalates the chance of getting other diseases and health issues, including heart disease, high blood pressure, and some sort of cancer. The gut microbiota may induce obesity through a multitude of processes, comprising energy balance control, LPS-stimulated inflammation, bile acids, and fat deposition control. Hence, the surge in obesity is anticipated to propel market growth in the coming years. As per the World Health Organization (WHO) figures, obesity affected more than 1 billion people across the globe by 2022, comprising 650 million adults, 340 million adolescents, and 39 million children.
-
Increasing Ratio of Autoimmune Diseases – Globally, the ratio of several kinds of autoimmune disorders such as celiac disease, Addison disease, multiple sclerosis, and so on has been growing. Any changes in the microbiota of the gastrointestinal tract have been correlated to autoimmune disorders. Thus, the surge in autoimmune diseases is projected to drive the growth of the market. For instance, currently, autoimmune disorders affecting around 24 million individuals in the United States, with women accounting for roughly 82% of those who are affected.
-
An Increase in the Development of Novel Microbiome – For instance, Persephone Biosciences Inc. began developing an immune-boosting microbiome therapeutic to help mitigate and fight the novel coronavirus (SARS-CoV-2) in April 2020, as well as a potential stool-based diagnostic test to assist in determining which patients are at the greatest chance of suffering from serious medical problems and mortality after suffering from COVID-19.
-
Rising Healthcare Expenditure - According to World Bank figures, worldwide healthcare expenditure increased by 9.83% in 2019.
Challenges
- Risk of Failure of the Concerned Research Projects - The research processed by numerous organizations on microbiome therapeutics is currently under different phases of clinical development. Organizations have invested massively in these research processes over the years with hopes for success in their efforts. Yet, the concern for the failure of the research projects, which would significantly impact their research investments is one of the major factor anticipated to hamper the market growth during the forecast period.
- Extreme Cost of Microbiome Therapeutics
- Stringent Regulatory Guidelines Imposed by the Government of Nations
Microbiome Therapeutics Market: Key Insights
Base Year |
2024 |
Forecast Year |
2025-2037 |
CAGR |
23.6% |
Base Year Market Size (2024) |
USD 531.37 million |
Forecast Year Market Size (2037) |
USD 8.59 billion |
Regional Scope |
|
Microbiome Therapeutics Segmentation
Application {Diabetes, Crohn's Disease, Clostridium Difficile Infection (CDI), Multiple Sclerosis, Rheumatoid Arthritis, Others}
The diabetes segment is estimated to gain largest market share of about 30% by 2037. The segment growth can be attributed to increasing prevalence of diabetes around the globe, coupled with the growing research and developments on the use of microbiome therapeutics for curing type 2 diabetes. According to the statistics by the Centers for Disease Control and Prevention (CDC), by the year 2022, around 37.3 million of the population of the United States had diabetes. Studies have reflected that gut bacteria play a fundamental role in diseases such as diabetes, especially type 2 diabetes. Type 2 diabetes is largely undiagnosed and is caused as of excessive body weight and physical inactivity. Research on the first human metagenome demonstrated the correlation between certain bacterial genes, specific intestinal bacteria, and their respective metabolic pathways with type 2 diabetes (T2D).
Product (Prebiotics, Probiotics, Symbiotics, and Others)
The probiotics segment is expected to garner a significant share of about 40% by 2037. The segment growth can be attributed to significant advantages of probiotics in the improvement of intestinal health, coupled with the improvement of lactose intolerance symptoms and the decrease of the risk of numerous other diseases. Probiotics are live good bacteria or yeasts that naturally exist in our body and are hugely advantageous for gut health. They aid in the maintenance of a healthy microorganism community in our body. Hence, currently, individuals are inclined to take probiotics for the benefit of digestive health. For instance, based on a consumer survey report, nearly 1/3 of individuals in the United States were keenly trying to consume probiotics, out of which around 61% were trying to use them on daily basis, and around 26% were trying to consume them several times within a day.
Our in-depth analysis of the global market includes the following segments:
By Type |
|
By Application |
|
By Product |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportMicrobiome Therapeutics Industry - Regional Synopsis
North American Market Forecast
The North American microbiome therapeutics market is set to account for 40% revenue share by the end of 2037. The market growth is impelled by significant presence of numerous established research facilities in the region for the development of novel therapeutics, followed by the rising healthcare expenditure and the presence of a population who are highly conscious of their health.
Based on the figures provided by the Center for Medicine and Medicaid Services (CMS), In 2021, healthcare spending in the United States increased by 2.7% to USD 4.3 trillion, or USD 12,914 per person. This healthcare expenditure accounted for 18.3% of the nation's gross domestic product. Further, the huge surge in the proportion of aged people, as well as the rise in the requirement for crohn's disease treatment will proliferate the market revenue.
Europe Market Forecast
The European microbiome therapeutics market is predicted to hold share of over 29% during the forecast period, due to presence of well-established research centers along with advantageous reimbursement policies. In addition, increasing approval for novel medications, and the huge ratio of investments received by start-ups for the research and development of microbiome-based products will propel the market size.
APAC Market Statistics
Further, the market in the Asia Pacific region is predicted to register massive CAGR through 2037. The market growth is led by escalating occurrence of inflammatory bowel disease, followed by the surge in diabetes cases in the region. In addition, rising initiatives for biological research in various countries in the region, coupled with the escalating awareness about novel therapeutics are also estimated to drive the market growth.

Companies Dominating the Microbiome Therapeutics Landscape
- YSOPIA Bioscience
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- 4D pharma plc
- Enterome
- BiomX Inc.
- Ferring International Center S.A.
- Vedanta Biosciences, Inc.
- Seres Therapeutics, Inc.
- Assembly Biosciences, Inc.
- Synlogic
- Finch Therapeutics Group, Inc.
In the News
-
Enterome has introduced the world's first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics therapeutic cancer vaccine, at the American Society of Clinical Oncology (ASCO) Annual Meeting.
-
Ferring International Center S.A. has received approval from the U.S. FDA for REBYOTA (fecal microbiota, live-jslm). It is a novel first-in-class microbiota-based live biotherapeutic denoted for the inhibition of recurrence of Clostridioides difficile infection (CDI) in individuals of 18 years of age and older, following antibiotic treatment for recurrent CDI.
Author Credits: Radhika Pawar
- Report ID: 2852
- Published Date: Jan 28, 2025
- Report Format: PDF, PPT